Byetta®
Manufacturer:
Amylin Pharmaceuticals, Inc. & Eli Lilly & Co.
More Information
|
The FDA is alerting health care professionals that
Byetta® may be associated with acute pancreatitis in some patients.
Byetta® is administered by a twice a day injection to treat type two
diabetes. More than 700,000 patients have used the drug since it was
released in 2005.
The FDA has reviewed 30 reports of individuals taking
Byetta® and developed acute pancreatitis. 21 of those
patients were hospitalized, five of them with serious complications.
22 of these individuals improved after discontinuing the drug.
Symptoms of acute pancreatitis are persistent and
severe abdominal pain possibly accompanied by vomiting.
If you or someone you know has sustained acute
pancreatitis or other damages while taking Byetta®, please contact us to
discuss your rights,
www.816LAWFIRM.com or
call us toll-free at 1-800-305-7552.
Call Peterson & Associates today &
Click Here.
|
| Byetta |
For more information:
Pharmaceutical Litigation
Prescription
Injury FAQs
Pharmaceutical Legal Glossary
Recent Byetta Headlines
>> Amylin Rises on Byetta Sales Data - TheStreet.com... - Mon, 17 Nov 2008
>> Feds deal a setback to new Byetta version - Indianapolis Star... - Thu, 06 Nov 2008
>> Amylin Slices Payroll by 340 Following Setbacks by Byetta - TMCnet... - Wed, 12 Nov 2008
>> Byetta uptick, Icahn news boost Amylin - FiercePharma... - Tue, 18 Nov 2008
>> Is Byetta the Next Rezulin or Avandia – Yet Another Promising Drug ...... - Wed, 19 Nov 2008
|
